Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002601 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00002601 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 13 participants.
The verdict
NCT00002601, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose combination chemotherapy and peripheral stem cell transplantation in treating patients who have advanced or recurrent sarcoma.
Interventions
- DRUG cisplatin
- DRUG melphalan
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1994-09 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002601
The ClinicalTrials.gov registry entry for NCT00002601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00002601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002601 about?
NCT00002601 is a clinical study titled "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumo...
What is the current status of trial NCT00002601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 1994-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00002601?
The interventions under investigation include: cisplatin (DRUG), melphalan (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002601?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.